Piper Jaffray Raises Price Target on Cepheid Stock | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has raised its price target on Cepheid's stock from $33 to $38, citing a European initiative aimed at C. difficile surveillance that could benefit the molecular diagnostics firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.